Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Seattle Genetics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Seattle Genetics, Inc. - Product Pipeline Review - 2014', provides an overview of the Seattle Genetics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Seattle Genetics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Seattle Genetics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Seattle Genetics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Seattle Genetics, Inc.'s pipeline products Reasons to buy - Evaluate Seattle Genetics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Seattle Genetics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Seattle Genetics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Seattle Genetics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seattle Genetics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Seattle Genetics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Seattle Genetics, Inc. Snapshot 5 Seattle Genetics, Inc. Overview 5 Key Information 5 Key Facts 5 Seattle Genetics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Seattle Genetics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Seattle Genetics, Inc. - Pipeline Products Glance 14 Seattle Genetics, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Seattle Genetics, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Seattle Genetics, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Seattle Genetics, Inc. - Drug Profiles 18 brentuximab vedotin 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SGN-CD19A 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 SGN-CD33A 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 SGN-LIV1A 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SGD-2083 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 SGN-CD70A 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Seattle Genetics, Inc. - Pipeline Analysis 29 Seattle Genetics, Inc. - Pipeline Products by Target 29 Seattle Genetics, Inc. - Pipeline Products by Route of Administration 31 Seattle Genetics, Inc. - Pipeline Products by Molecule Type 32 Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action 33 Seattle Genetics, Inc. - Recent Pipeline Updates 35 Seattle Genetics, Inc. - Dormant Projects 51 Seattle Genetics, Inc. - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 dacetuzumab 52 lintuzumab 52 SGN-15 52 vorsetuzumab 53 vorsetuzumab mafodotin 53 Seattle Genetics, Inc. - Company Statement 54 Seattle Genetics, Inc. - Locations And Subsidiaries 57 Head Office 57 Other Locations & Subsidiaries 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Seattle Genetics, Inc., Key Information 5 Seattle Genetics, Inc., Key Facts 5 Seattle Genetics, Inc. - Pipeline by Indication, 2014 8 Seattle Genetics, Inc. - Pipeline by Stage of Development, 2014 9 Seattle Genetics, Inc. - Monotherapy Products in Pipeline, 2014 10 Seattle Genetics, Inc. - Partnered Products in Pipeline, 2014 11 Seattle Genetics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Seattle Genetics, Inc. - Phase III, 2014 14 Seattle Genetics, Inc. - Phase II, 2014 15 Seattle Genetics, Inc. - Phase I, 2014 16 Seattle Genetics, Inc. - Preclinical, 2014 17 Seattle Genetics, Inc. - Pipeline by Target, 2014 30 Seattle Genetics, Inc. - Pipeline by Route of Administration, 2014 31 Seattle Genetics, Inc. - Pipeline by Molecule Type, 2014 32 Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action, 2014 34 Seattle Genetics, Inc. - Recent Pipeline Updates, 2014 35 Seattle Genetics, Inc. - Dormant Developmental Projects,2014 51 Seattle Genetics, Inc. - Discontinued Pipeline Products, 2014 52 Seattle Genetics, Inc., Subsidiaries 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.